TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T01991 XX ID T01991 XX DT 02.12.1996 (created); hiwi. DT 11.03.2015 (updated); sup. CO Copyright (C), QIAGEN. XX FA Fra-2 XX SY Fos related antigen 2; Fos-like antigen 2; FOSL2; Fra2. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G004688 FOSL2; HGNC: FOSL2. XX CL C0008; bZIP; XX SF the heterodimer with c-Jun bends DNA similar as the c-Fos/c-Jun complex, but with a smaller bending angle [1]; SF the heterodimer with CRE-BP1/ATF-2 T00167 induces a bending towards the minor groove which is slightly lower than that caused by c-Fos/CRE-BP1 [1]; XX CP widespread; human endometrium from proliferative and secretory phases of the menstrual cycle and human decidua from early pregnancy [7]. CN T cells, B cells (probably) [5]. XX FF lacks the C-terminal trans-activation domain of c-Fos and does not exhibit transforming activity [3]; FF may be involved in G0-G1 transition [4]; FF gene is induced by phorbol ester with slower kinetics than c-fos or fra-1 [5]; XX IN T00968 ATF-1; human, Homo sapiens. IN T00167 ATF-2-isoform1; human, Homo sapiens. IN T01113 Elf-1; human, Homo sapiens. IN T05220 Evi-1; human, Homo sapiens. IN T10210 Evi-1; human, Homo sapiens. IN T02368 HMGIY; human, Homo sapiens. IN T00437 JunD; mouse, Mus musculus. XX MX M00924 V$AP1_Q2_01. MX M00926 V$AP1_Q4_01. MX M00925 V$AP1_Q6_01. MX M07092 V$FOSL2_02. MX M08914 V$FRA2_01. MX M08915 V$FRA2_02. MX M03870 V$FRA2_Q4_01. XX BS R21775. BS R62338. BS R41978. BS R14540. BS R26802. BS R31706. BS R31708. BS R41737. BS R28305. BS R29092. BS R30937. BS R14544. BS R26674. BS R72604. BS R14725. BS R26758. BS R39281. BS R66690. BS R59837. BS R26793. BS R34900. BS R35944. BS R60863. BS R36611. BS R38461. BS R29975. BS R14478. BS R14480. BS R21738. BS R33879. XX DR TRANSPATH: MO000026074. DR TRANSCOMPEL: C00418. DR UniProtKB: P15408; XX RN [1]; RE0004643. RX PUBMED: 8355695. RA Kerppola T. K., Curran T. RT Selective DNA bending by a variety of bZIP proteins RL Mol. Cell. Biol. 13:5479-5489 (1993). RN [2]; RE0004788. RX PUBMED: 8415709. RA Kameda T., Akahori A., Sonobe M. H., Suzuki T., Endo T., Iba H. RT JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2 RL Proc. Natl. Acad. Sci. USA 90:9369-9373 (1993). RN [3]; RE0004817. RX PUBMED: 7504176. RA Wisdom R., Verma I. M. RT Transformation by Fos proteins requires a C-terminal transactivation domain RL Mol. Cell. Biol. 13:7429-7438 (1993). RN [4]; RE0004865. RX PUBMED: 1406676. RA Kovary K., Bravo R. RT Existence of different Fos/Jun complexes during the G0-to-G1 transition and during exponential growth in mouse fibroblasts: differential role of Fos proteins RL Mol. Cell. Biol. 12:5015-5023 (1992). RN [5]; RE0004893. RX PUBMED: 2107490. RA Matsui M., Tokuhara M., Konuma Y., Nomura N., Ishizaki R. RT Isolation of human fos- related genes and their expression during monocyte-macrophage differentiation RL Oncogene 5:249-255 (1990). RN [6]; RE0016689. RX PUBMED: 7648395. RA Bassuk A. G., Leiden J. M. RT A direct physical association between ETS and AP-1 transcription factors in normal human T cells. RL Immunity 3:223-237 (1995). RN [7]; RE0034082. RX PUBMED: 11266514. RA Watanabe K., Kessler C. A., Bachurski C. J., Kanda Y., Richardson B. D., Stanek J., Handwerger S., Brar A. K. RT Identification of a decidua-specific enhancer on the human prolactin gene with two critical activator protein 1 (AP-1) binding sites. RL Mol. Endocrinol. 15:638-53 (2001). RN [8]; RE0066649. RX PUBMED: 16984917. RA Byun H. J., Hong I. K., Kim E., Jin Y. J., Jeoung D. I., Hahn J. H., Kim Y. M., Park S. H., Lee H. RT A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. RL J. Biol. Chem. 281:34833-34847 (2006). XX //